aTyr Pharma Inc. is developing therapies targeting fibrosis and inflammation through a proprietary tRNA synthetase biology platform, focusing on interstitial lung diseases (ILD). Its lead candidate, efzofitimod, recently reported mixed Phase 3 results in pulmonary sarcoidosis, missing the primary corticosteroid reduction endpoint but showing nominal improvements in quality of life measures. The company remains pre-commercial, operating at sustained losses with limited cash reserves and a significant accumulated deficit. Future prospects depend on regulatory engagement outcomes, further clinical development, and capital raising efforts.